APO Research
Talk to an analyst

APO RESEARCH · REPORT

Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

Selected research

Market Analysis & Forecast

Global Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast 2026-2032

20 December 2025196 pages

Choose your research edition.

Industry ResearchInduced Pluripotent Stem Cells (iPSCs) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Induced Pluripotent Stem Cells (iPSCs) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Induced Pluripotent Stem Cells (iPSCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Induced Pluripotent Stem Cells (iPSCs) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Induced Pluripotent Stem Cells (iPSCs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.

United States is the largest Induced Pluripotent Stem Cells (iPSCs) market with about 43% market share. Europe is follower, accounting for about 33% market share.

The key players are Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo Dainippon Pharma, Astellas Pharma Inc, Fate Therapeutics, Inc, Pluricell Biotech, Cell Inspire Biotechnology, ReproCELL etc. Top 3 companies occupied about 73% market share.

Read the full market overview

Report Includes

This report presents an overview of global market for Induced Pluripotent Stem Cells (iPSCs), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Induced Pluripotent Stem Cells (iPSCs), also provides the revenue of main regions and countries. Of the upcoming market potential for Induced Pluripotent Stem Cells (iPSCs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Induced Pluripotent Stem Cells (iPSCs) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Induced Pluripotent Stem Cells (iPSCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Induced Pluripotent Stem Cells (iPSCs) revenue, projected growth trends, production technology, application and end-user industry.

Induced Pluripotent Stem Cells (iPSCs) Segment by Company

Fujifilm Holding Corporation (CDI)

Ncardia

Sumitomo Dainippon Pharma

Astellas Pharma Inc

Fate Therapeutics, Inc

Pluricell Biotech

Cell Inspire Biotechnology

ReproCELL

Induced Pluripotent Stem Cells (iPSCs) Segment by Type

Human iPSCs

Mouse iPSCs

Induced Pluripotent Stem Cells (iPSCs) Segment by Application

Academic Research

Drug Development and Discovery

Toxicity Screening

Regenerative Medicine

Others

Induced Pluripotent Stem Cells (iPSCs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Induced Pluripotent Stem Cells (iPSCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Induced Pluripotent Stem Cells (iPSCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Induced Pluripotent Stem Cells (iPSCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Induced Pluripotent Stem Cells (iPSCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Induced Pluripotent Stem Cells (iPSCs) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Induced Pluripotent Stem Cells (iPSCs) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Human iPSCs Major Player Table 3. Mouse iPSCs Major Player Table 4. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Academic Research Major Player Table 6. Drug Development and Discovery Major Player Table 7. Toxicity Screening Major Player Table 8. Regenerative Medicine Major Player Table 9. Others Major Player Table 10. Induced Pluripotent Stem Cells (iPSCs) Industry Trends Table 11. Induced Pluripotent Stem Cells (iPSCs) Industry Drivers Table 12. Induced Pluripotent Stem Cells (iPSCs) Industry Opportunities and Challenges Table 13. Induced Pluripotent Stem Cells (iPSCs) Industry Restraints Table 14. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Region (2021-2026) Table 17. Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Region (2027-2032) Table 19. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Players (2021-2026) Table 21. Global Induced Pluripotent Stem Cells (iPSCs) Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Induced Pluripotent Stem Cells (iPSCs) Key Players Headquarters & Area Served Table 23. Global Induced Pluripotent Stem Cells (iPSCs) Players, Product Type & Application Table 24. Global Induced Pluripotent Stem Cells (iPSCs) Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Induced Pluripotent Stem Cells (iPSCs) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2021-2026) Table 31. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2027-2032) Table 32. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2021-2026) Table 36. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2027-2032) Table 37. Fujifilm Holding Corporation (CDI) Company Information Table 38. Fujifilm Holding Corporation (CDI) Business Overview Table 39. Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 41. Fujifilm Holding Corporation (CDI) Recent Development Table 42. Ncardia Company Information Table 43. Ncardia Business Overview Table 44. Ncardia Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Ncardia Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 46. Ncardia Recent Development Table 47. Sumitomo Dainippon Pharma Company Information Table 48. Sumitomo Dainippon Pharma Business Overview Table 49. Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 51. Sumitomo Dainippon Pharma Recent Development Table 52. Astellas Pharma Inc Company Information Table 53. Astellas Pharma Inc Business Overview Table 54. Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 56. Astellas Pharma Inc Recent Development Table 57. Fate Therapeutics, Inc Company Information Table 58. Fate Therapeutics, Inc Business Overview Table 59. Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 61. Fate Therapeutics, Inc Recent Development Table 62. Pluricell Biotech Company Information Table 63. Pluricell Biotech Business Overview Table 64. Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 66. Pluricell Biotech Recent Development Table 67. Cell Inspire Biotechnology Company Information Table 68. Cell Inspire Biotechnology Business Overview Table 69. Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 71. Cell Inspire Biotechnology Recent Development Table 72. ReproCELL Company Information Table 73. ReproCELL Business Overview Table 74. ReproCELL Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. ReproCELL Induced Pluripotent Stem Cells (iPSCs) Product Portfolio Table 76. ReproCELL Recent Development Table 77. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (US$ Million) & (2027-2032) Table 91. China Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026) & (US$ Million) Table 92. China Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032) & (US$ Million) Table 93. China Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026) & (US$ Million) Table 94. China Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Induced Pluripotent Stem Cells (iPSCs) Image Figure 2. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Human iPSCs Image Figure 5. Mouse iPSCs Image Figure 6. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Induced Pluripotent Stem Cells (iPSCs) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Academic Research Image Figure 9. Drug Development and Discovery Image Figure 10. Toxicity Screening Image Figure 11. Regenerative Medicine Image Figure 12. Others Image Figure 13. Global Induced Pluripotent Stem Cells (iPSCs) Market Size (US$ Million) & (2021-2032) Figure 14. Global Induced Pluripotent Stem Cells (iPSCs) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Induced Pluripotent Stem Cells (iPSCs) Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Induced Pluripotent Stem Cells (iPSCs) Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2021-2032) Figure 21. Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2021-2032) Figure 24. North America Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032) Figure 26. North America Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032) Figure 27. North America Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Country (2021-2032) Figure 28. United States Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032) Figure 33. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032) Figure 34. Europe Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Country (2021-2032) Figure 35. Germany Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032) Figure 45. China Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032) Figure 46. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032) Figure 48. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032) Figure 49. Asia Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Region (2021-2032) Figure 50. Japan Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032) Figure 58. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032) Figure 59. SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Country (2021-2032) Figure 60. Brazil Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Induced Pluripotent Stem Cells (iPSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Human iPSCs
  • Mouse iPSCs
Applications
  • Academic Research
  • Drug Development and Discovery
  • Toxicity Screening
  • Regenerative Medicine
  • Others
Companies covered
  • Fujifilm Holding Corporation (CDI)
  • Ncardia
  • Sumitomo Dainippon Pharma
  • Astellas Pharma Inc
  • Fate Therapeutics, Inc
  • Pluricell Biotech
  • Cell Inspire Biotechnology
  • ReproCELL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Induced Pluripotent Stem Cells (iPSCs) Market by Type
  3. 1.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Human iPSCs
  5. 1.2.3 Mouse iPSCs
  6. 1.3 Induced Pluripotent Stem Cells (iPSCs) Market by Application
  7. 1.3.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Academic Research
  9. 1.3.3 Drug Development and Discovery
  10. 1.3.4 Toxicity Screening
  11. 1.3.5 Regenerative Medicine
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Induced Pluripotent Stem Cells (iPSCs) Market Dynamics
  1. 2.1 Induced Pluripotent Stem Cells (iPSCs) Industry Trends
  2. 2.2 Induced Pluripotent Stem Cells (iPSCs) Industry Drivers
  3. 2.3 Induced Pluripotent Stem Cells (iPSCs) Industry Opportunities and Challenges
  4. 2.4 Induced Pluripotent Stem Cells (iPSCs) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Perspective (2021-2032)
  2. 3.2 Global Induced Pluripotent Stem Cells (iPSCs) Growth Trends by Region
  3. 3.2.1 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2021-2026)
  5. 3.2.3 Global Induced Pluripotent Stem Cells (iPSCs) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Players
  2. 4.1.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Players (2021-2026)
  3. 4.1.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Induced Pluripotent Stem Cells (iPSCs) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Induced Pluripotent Stem Cells (iPSCs) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Induced Pluripotent Stem Cells (iPSCs) Key Players Headquarters & Area Served
  7. 4.4 Global Induced Pluripotent Stem Cells (iPSCs) Players, Product Type & Application
  8. 4.5 Global Induced Pluripotent Stem Cells (iPSCs) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Induced Pluripotent Stem Cells (iPSCs) Market CR5 and HHI
  11. 4.6.3 2025 Induced Pluripotent Stem Cells (iPSCs) Tier 1, Tier 2, and Tier 3
5 Induced Pluripotent Stem Cells (iPSCs) Market Size by Type
  1. 5.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2032)
  3. 5.3 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Type (2021-2032)
6 Induced Pluripotent Stem Cells (iPSCs) Market Size by Application
  1. 6.1 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2032)
  3. 6.3 Global Induced Pluripotent Stem Cells (iPSCs) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Fujifilm Holding Corporation (CDI)
  2. 7.1.1 Fujifilm Holding Corporation (CDI) Company Information
  3. 7.1.2 Fujifilm Holding Corporation (CDI) Business Overview
  4. 7.1.3 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Fujifilm Holding Corporation (CDI) Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  6. 7.1.5 Fujifilm Holding Corporation (CDI) Recent Developments
  7. 7.2 Ncardia
  8. 7.2.1 Ncardia Company Information
  9. 7.2.2 Ncardia Business Overview
  10. 7.2.3 Ncardia Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ncardia Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  12. 7.2.5 Ncardia Recent Developments
  13. 7.3 Sumitomo Dainippon Pharma
  14. 7.3.1 Sumitomo Dainippon Pharma Company Information
  15. 7.3.2 Sumitomo Dainippon Pharma Business Overview
  16. 7.3.3 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sumitomo Dainippon Pharma Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  18. 7.3.5 Sumitomo Dainippon Pharma Recent Developments
  19. 7.4 Astellas Pharma Inc
  20. 7.4.1 Astellas Pharma Inc Company Information
  21. 7.4.2 Astellas Pharma Inc Business Overview
  22. 7.4.3 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Astellas Pharma Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  24. 7.4.5 Astellas Pharma Inc Recent Developments
  25. 7.5 Fate Therapeutics, Inc
  26. 7.5.1 Fate Therapeutics, Inc Company Information
  27. 7.5.2 Fate Therapeutics, Inc Business Overview
  28. 7.5.3 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Fate Therapeutics, Inc Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  30. 7.5.5 Fate Therapeutics, Inc Recent Developments
  31. 7.6 Pluricell Biotech
  32. 7.6.1 Pluricell Biotech Company Information
  33. 7.6.2 Pluricell Biotech Business Overview
  34. 7.6.3 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pluricell Biotech Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  36. 7.6.5 Pluricell Biotech Recent Developments
  37. 7.7 Cell Inspire Biotechnology
  38. 7.7.1 Cell Inspire Biotechnology Company Information
  39. 7.7.2 Cell Inspire Biotechnology Business Overview
  40. 7.7.3 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Cell Inspire Biotechnology Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  42. 7.7.5 Cell Inspire Biotechnology Recent Developments
  43. 7.8 ReproCELL
  44. 7.8.1 ReproCELL Company Information
  45. 7.8.2 ReproCELL Business Overview
  46. 7.8.3 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ReproCELL Induced Pluripotent Stem Cells (iPSCs) Product Portfolio
  48. 7.8.5 ReproCELL Recent Developments
8 North America
  1. 8.1 North America Induced Pluripotent Stem Cells (iPSCs) Revenue (2021-2032)
  2. 8.2 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2032)
  3. 8.2.1 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026)
  4. 8.2.2 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032)
  5. 8.3 North America Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032)
  6. 8.4 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2032)
  7. 8.4.1 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026)
  8. 8.4.2 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032)
  9. 8.5 North America Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032)
  10. 8.6 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country
  11. 8.6.1 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026)
  13. 8.6.3 North America Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue (2021-2032)
  2. 9.2 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032)
  5. 9.3 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032)
  9. 9.5 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country
  11. 9.6.1 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Induced Pluripotent Stem Cells (iPSCs) Revenue (2021-2032)
  2. 10.2 China Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2032)
  3. 10.2.1 China Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026)
  4. 10.2.2 China Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032)
  5. 10.3 China Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032)
  6. 10.4 China Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2032)
  7. 10.4.1 China Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026)
  8. 10.4.2 China Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032)
  9. 10.5 China Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue (2021-2032)
  2. 11.2 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032)
  5. 11.3 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032)
  9. 11.5 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Country
  11. 11.6.1 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue (2021-2032)
  2. 12.2 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country
  11. 12.6.1 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Induced Pluripotent Stem Cells (iPSCs) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst